In this review, Japanese experience of cytoreductive surgery and perioperative chemotherapy is described. The new concept of peritoneal metastasis (PM) type, i.e., trans-mesothelial, trans-lymphatic, and superficial growing metastasis type was proposed in 2012. Surgeons should perform peritonectomy according to the type of PM. Since 1980, Japanese surgical oncologists have been spearheading the use of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemoperfusion (HIPEC) as treatment for PM from gastric cancer. Two RCTs were conducted to verify the effect of HIPEC for the prophylaxis of peritoneal recurrence after curative resection of advanced gastric cancer. These two studies indicated that HIPEC is effective in preventing peritoneal recurrence of gastric cancer with serosal invasion. In 2002, intraperitoneal chemotherapy using taxans was developed for the treatment of PM from gastric cancer and led to the development of neoadjuvant intraperitoneal/systemic chemotherapy (NIPS), which was reported in 2006. In 2009, extensive intra-operative peritoneal lavage (EIPL) was developed, and contributed to the remarkable improvement in survival of patients with positive lavage cytology as demonstrated by prospective randomized clinical trials. In 2017, the Peritoneal Surface Oncology Group International proposed the value of complete cytoreduction and peritoneal cancer index cut-off as independent prognostic factors after CRS for gastric cancer with PM. Founded in 2016, the Japanese/Asian School of Peritoneal Surface Oncology (JASPSO) trains beginners to perform CRS and HIPEC safely. Sixteen students have already graduated from JASPSO and started to perform the treatment in their home countries.
Introduction
Until the late 1990s, peritoneal metastasis (PM) was considered a terminal stage, and almost all patients with PM died of the disease within a median of 5-7 months after palliative systemic chemotherapy or surgery alone [1, 2] .
An innovative treatment for PM (hyperthermic intraperitoneal chemoperfusion (HIPEC)) was developed in 1980 by Spratt, who reported the first case successfully treated with HIPEC [3] . HIPEC has been used since then for the treatment of peritoneal metastasis (PM) from gastrointestinal cancer, and new regimens of systemic chemotherapy have been developed and used to treat PM since the late 1990s. However, the prognosis of patients with PM was poor after HIPEC or systemic chemotherapy alone [4, 5] .
In 1995, Sugarbaker developed a new surgical technique of complete removal of PM named Bperitonectomy^ [6] . In the late 1990s, a paradigm shift occurred in the treatment of PM. Since PM is considered a local disease, confined to the peritoneal cavity, a combination therapy with cytoreductive surgery (CRS) using peritonectomy to remove macroscopic detectable PM and perioperative chemotherapy (POC) to eradicate micrometastases was proposed by the Peritoneal Surface Oncology Group International (PSOGI). This strategy is considered a comprehensive treatment that improves the longterm survival [7] [8] [9] [10] , and a curative approach in selected patients with limited PM [11] . In this review, the history and the present status of the treatment of PM in Japan will be described.
History of Peritoneal Surface Oncology in Japan

New Concept of Peritoneal Metastasis Formation
The establishment of PM has long been considered a multi-step process, consisting of (1) detachment of tumor cells from the primary tumor (peritoneal free cancer cells, PFCCs), (2) attachment of PFCCs to distant peritoneal surfaces, (3) invasion of PFCCs into the submesothelial tissue, and (4) proliferation accompanied by angiogenesis and the induction of stromal tissue [12] . The process was named Btrans-mesothelial metastasis^by Yonemura [13] and Brandomly proximal distribution^by Sugarbaker [14] (Fig. 1) . At the completion of the process, cancer cells show step-by-step expression of metastasis-related proteins, such as adhesion molecules, motility factors, matrix digesting enzymes, and angiogenesis factors [13] . In 2012, Yonemura reported new pathways of metastasis, called Btranslymphatic metastasis^and Bsuperficially growing metastasis.Î n trans-lymphatic metastasis, PFCCs migrate into the submesothelial lymphatic vessels through mesothelial stomata and holes of macula cribriformis under the mesothelial basement membrane [15] . Macula cribriformis is a collagen plate below the mesothelial basement membrane with many holes, with which blind tips of initial lymphatic vessels connect. Subperitoneal lymphatic vessels, used for trans-lymphatic dissemination, are called initial lymphatics and are found in omental milky spots, parietal peritoneum, and small bowel mesentery. Omental milky spots absorb peritoneal fluid [16] , and intraperitoneal inflammatory cells and PFCCs migrate into the initial lymphatic vessels of milky spots [17, 18] (Fig. 2-A) . Initial lymphatic vessels have blind loops that extend from the submesothelial lymphatic plexus and blind tips that attach to the holes in the macula cribriformis ( Fig. 2-B) . PFCCs migrate into the initial lymphatic vessels and proliferate in the lymphatic plexus (Fig. 2-C) . The triplet structure of the peritoneum consisting of mesothelial stomata, holes in the macula cribriformis, and initial lymphatic vessels is essential for the formation of trans-lymphatic metastasis (Fig. 2 -broken circle) Figure 3 . These structures are detected on the parietal peritoneum but not the peritoneum on the anterior upper abdominal wall. The peritoneum of the diaphragm, pelvis, paracolic gutter, Morrison's pouch, and perihepatic ligaments has a triplet structure but not milky spots. The size of the holes in the macula cribriformis ranges from 5 to 30 μm. In the experimental study, intraperitoneally injected cancer cells induce mesothelial cell contraction and appear in submesothelial lymphatic vessels on day 3 after injection [17] . Clinically, trans-lymphatic metastasis is found in gastric, colorectal, and pancreatic cancer [15] .
In contrast, PFCCs from appendiceal mucinous neoplasm (AMN) cannot metastasize through the trans-mesenteric or trans-lymphatic route because PFCCs from AMN are covered with mucinous material and too large (Fig. 4) . However, AMN can establish PM in particular peritoneal areas.
PFCCs of AMN settle on the pelvic peritoneal surface by gravity, or adsorbed to the omental milky spots or diaphragmatic stomata (Figs. 3-B glycoprotein expressed on the surface of interstitial stem cells and immature vascular endothelial cells [19] . CD34 inhibits tissue maturation, and disappears once maturation is complete. These stromal cells in immature interstitial tissue induce neovascularization from subperitoneal blood capillaries (Fig. 4 ).
This metastasis pattern is named Bsuperficially growing metastasis^by Yonemura ( Fig. 5 ) [11] and Bredistribution pattern^by Sugarbaker [14] .
Surgeons should understand the mechanisms of PM formation, and choose to perform peritonectomy options according to the metastatic pattern. History of HIPEC, Neoadjuvant Intraperitoneal/Systemic Chemotherapy, and Laparoscopic HIPEC in Japan
After the first clinical application of HIPEC in1980 by Spratt, the Japanese surgical oncologist S. Koga began studying HIPEC, and reported the first clinical results of his trial of HIPEC for PM from gastric cancer in 1983 [20] . Then, Yonemura began treating gastric cancer patients with PM using HIPEC in 1986, and reported a case of complete disappearance of PM after HIPEC [21] . Since then, many clinical studies of treatment for PM from gastric and colorectal cancer have been performed [22, 23] . Fujimoto reported a better 3-year survival rate among patients receiving HIPEC + gastrectomy group than gastrectomy alone (46% vs 16%) [23] . Yamaguchi used HIPEC to treat PM from colorectal cancer, and reported significantly longer survival among complete responders [22] .
In 1991, Yonemura et al. reported the survival improvement and safety of CRS plus HIPEC for PM from gastric cancer [24] . However, the 5-year (long-term) survival rate remained insufficient.
In 2002, intraperitoneal (IP) administration of taxan compounds was introduced as a gastric cancer treatment [25] . The IP taxan treatment was safe and had a pharmacologic advantage at peritoneal surface [25] .
In 2006, Yonemura developed a new bidirectional chemotherapy using IP docetaxel and carboplatin combined with intravenous (IV) methotrexate and 5-fluorouracil [26] . This method was named Bneoadjuvant intraperitoneal/systemic chemotherapy (NIPS),^and was believed to increase the treatment area.
In 2010, more powerful NIPS using IP/IVadministration of docetaxel and cisplatin in combination with oral administration of S1 was developed [27] . The method effectively reduced peritoneal cancer index (PCI) and eradicated PFCCs [28, 29] . After introduction of NIPS plus CRS for gastric cancer PM, long-term survival was significantly improved, and 5-year survival rates were reported at 18 to 24% [8, 30] .
In gastric cancer, complete cytoreduction (CCR-0) is essential for long-term survival [8] . However, CCR-0 can be performed in only 30% of patients with PM at the time of diagnosis [31] . Additionally, PCI cut-off value is an important prognostic factor. All patients with PCI higher than the cut-off level had poor prognosis and died even after complete cytoreduction. In contrast, postoperative survival was significantly more favorable in patients with PCI lower than the cut-off level [8, 9, 32] . According to the meta-analysis by Coccolini F, the PCI cut-off level should be 12 [8] . However, PCI evaluated by preoperative imaging (computed tomography, positron emission tomography) is inaccurate, if the diameter of PM is less than 8 mm [33] [34] [35] . Accordingly, PCI should be diagnosed by laparoscopy before CRS. Patients whose PCI is higher than the cut-off level should be excluded from CRS. Since 2012, HIPEC has been performed on the day of exploratory laparoscopy. Consequently, the method is known as Blaparoscopic HIPEC (LHIPEC).^LHIPEC (or closed HIPEC) (relative to open HIPEC as performed under laparotomy) achieves significantly greater drug penetration from the peritoneal surface because intraperitoneal pressure is significantly higher in closed HIPEC [36] . Accordingly, LHIPEC is expected to be more effective than open-type HIPEC.
In 2017, Yonemura first reported the direct effect of HIPEC on PM from gastric cancer in patients treated by LHIPEC [37] . From 2013 to 2016, a total of 53 patients with PM from gastric cancer received LHIPEC two times separated by a 1-month rest interval. Changes in PCI and cytologic status were studied at the time of the first and second laparoscopy. LHIPEC effectively eradicated peritoneal free cancer cells and reduced PCI. Previously, peritoneal cytologic status at CRS had been reported to relate significantly to survival after CRS [38] . In the LHIPEC group, cytology changed from positive to negative in 13 (68%) of 19 patients at the second laparoscopy. Additionally, eight (15%) patients showed complete disappearance of PM and significant reduction of PCI from 14.2 ± 10.7 at the first LHIPEC to 11.8 ± 11.0 at the second laparoscopy.
Additionally, another study was performed after 1 cycle of LHIPEC plus 3 cycles of NIPS. As a result, six (11.5%) patients showed complete disappearance of PM and significantly reduced PCI from 14.8 ± 11.4 at the first LHIPEC to 9.9 ± 11.3 LHIPEC plus 3 cycles of NIPS (P < 0.0001). Adding 3 cycles of NIPS, effectively doubled the mean reduction in PCI levels, significantly increased the number of patients with PCI ≤ 11 from 23 (44.2% of 52 patients) to 35 (67.3%), and changed peritoneal cytology from positive to negative in 22 (71%) of 31patients.
Diffuse involvement of the small bowel and its mesentery is the limiting factor for complete cytoreduction. Yonemura reported that all patients with small bowel PCI ≥ 3 died of disease even after complete cytoreduction [32] . LHIPEC plus 3 cycles of NIPS significantly reduced small bowel PCI. In 2016, PSOGI reported that CCR-0, PCI less than the cut-off value, and small bowel PCI ≤ 2 were the independent prognostic factors [28] . Accordingly, combining LHIPEC and NIPS is a powerful method to reduce small bowel PCI, thereby increasing the complete cytoreduction rate.
No grade 3, 4, or 5 complications of LHIPEC were found, and grade 3 complications of LHIPEC plus NIPS developed in only four patients (7.7%). Accordingly, LHIPEC plus NIPS can be done safely.
Development of a New Method for Detecting Small Peritoneal Metastasis
Even after CCR-0 resection for PM from gastric and colorectal cancer, peritoneal recurrence developed in about 70% of patients [38, 39] . One of the causes of recurrence had to be small PM overlooked by naked eye or palpation during the operation. A new method of detecting PM, named Bphotodynamic detection (PDD),^using 5-aminolevulinic acid (ALA) was developed. ALA is the natural precursor of protoporphyrin (Pp) IX and heme. In the heme synthesis pathway, ALA is converted to PpIX. After its excess administration, ALA accumulates in cancer cells through the action of the ALA influx transporter on cancer cell membrane. As a result, intracellular PpIX synthesis increases, and PpIX accumulates in cancer cells. PpIX in cancer cells emits a red fluorescence in violet right at 405 nm and renders detectable any PM of diameter of 0.1 mm (Fig. 6 ) [40] [41] [42] .
Initially, PDD for PM had been proposed in an animal model [43] . Normal peritoneum does not photoemit when excited by violet light because of the low PpIX content of normal mesothelial cells [44] . ALA-positive rates were higher in PM from pancreatic cancer, ovarian cancer, colorectal cancer, biliary cancer, small bowel cancer, and mesothelioma (ranging from 50 to 85%), but low in gastric cancer after NIPS and appendiceal mucinous neoplasm. PpIX content was significantly higher in ALA-positive PM than ALA-negative nodules. The PpIX content of PM depends on the expression of the ALA influx transporter, porphyrin efflux transporter [44, 45] , and ferrochelatase. There have been no reported permanent side effects of ALA and no transient side effects except transient erythema and nausea [44] [45] [46] [47] [48] . ALA PDD is a safe and feasible method of small PM detection, and is indicated for ovarian cancer, mesothelioma, pancreatic cancer, colorectal cancer, biliary cancer, and small bowel cancer [44] .
Training Program for CRS and HIPEC in Japan
Morbidity and mortality rates were reported to be significantly higher for those receiving CRS plus HIPEC than those receiving traditional palliative surgery. Between 16 and 68% of patients experienced grade 3 or 4 toxicity according to the common grading criteria and 7-11% of patients needed reoperation [49, 50] . Reported mortality rates were 0-9% [49] [50] [51] . Surgeons who want to provide the comprehensive treatment should be very knowledgeable about surgical skills, anatomy, physiology, oncology, chemotherapy, postoperative care, and nutrition, To perform CRS + HIPEC safely within mortality and morbidity limits, beginners have to be trained to carry out the operation techniques, HIPEC methods, and postoperative care under the guidance of experts. The reported learning curve is about 70-130 cases [52, 53] . Peritoneal Surface Oncology Group International (POSGI) started a training program for beginners in 2014 in Europe. The European School of Peritoneal Surface Oncology (ESPSO) is a joint venture of the European Society of Surgical Oncology (ESSO) and PSOGI. The target audience of this 2-year program is chief residents, fellow surgeons, consultant surgeons, gynecologists, and medical oncologists. Topics covered by the training program include (1) peritoneal carcinomatosis (overview and surgical techniques); (2) peritoneal carcinomatosis from colorectal cancer, ovarian cancer, gastric cancer, pseudomyxoma peritonei, and rare peritoneal surface malignancies; (3) palliative care; and (4) experimental and translational research. In addition, students have to attend a special training course held twice a year. Upon successful completion of this program, the candidates obtain European accreditation in Peritoneal Surface Oncology.
In 2016, the Japanese/Asian School of Peritoneal Surface Oncology (JASPSO) was founded as a joint venture with PSOGI. It provides adequate and structured training in the management of PM. Students receive highly specialized knowledge and learn to master the complexity of aggressive CRS combined with NIPS, LHIPEC, HIPEC, early postoperative chemotherapy (EPIC), and systemic chemotherapy. JASPSO's director is Yutaka Yonemura, and basic and advanced training is provided at Kishiwada Tokushukai Hospital (Osaka) and Kusatsu General Hospital (Shiga). Since 2016, JASPSO has trained 16 students from foreign countries.
The Health Care Structure in Japan and Insurance Coverage for Comprehensive Treatment
At present, the combination of CRS and HIPEC is considered to be standard of care in selected patients with PM from colorectal cancer. However, health insurance coverage for the treatment is different from country to country. Bushati studied the health care structure by web-based survey of 19 expert surgeons from 19 different countries (Australia, Belgium, Brazil, Canada, China, Denmark, France, Germany, Greece, India, Italy, Japan, Netherlands, Singapore, Spain, Sweden, Peritoneal metastases were red-fluorescent and small but at least 0.1 mm in diameter can be detected Switzerland, UK, and USA) [54] . CRS plus HIPEC was included in the national guideline in 16 of 19 countries and was approved for reimbursement by health insurance in 17 of 19 countries.
The Japanese guideline for colorectal PM designates CRS plus HIPEC as an experimental treatment and not a recommended treatment. Accordingly, the fee for CRS with HIPEC is not covered by insurance in Japan.
Peritoneal Surface Malignancy Centers in Japan
According to Bushati, more than 430 centers worldwide currently perform CRS + HIPEC, and more than 3800 colorectal cancer patients with PM worldwide annually receive CRS plus HIPEC [54] . There is a huge variation in the number of HIPEC centers per 1 million inhabitants per country, ranging from 0.007 in China to 1.8 in Switzerland.
In Japan, CRS plus HIPEC and HIPEC alone are performed in two and four centers, respectively. The number of CRS plus HIPEC centers in Japan is 0.015 per 1 million inhabitants. In the two big centers of Kishiwada Tokusyukai Hospital and Kusatsu General Hospital, there were 329 CRS + HIPECs and 118 LHIPECs were performed in 2017. During the last 10 years, 2351 patients were treated by CRS with or without HIPEC, and CCR-0 resection was performed in 1431 (61%) patients. Five-year survival rates after CCR-0 resection for patients with PM from pseudomyxoma peritonei, gastric cancer, colorectal cancer, ovarian cancer, mesothelioma, and small bowel cancer were 84%, 14%, 27%, 67%, 40%, and 46%, respectively.
The Contribution of Japan to Peritoneal Surface Oncology-What it Has Given to the World Since 1980, Japanese surgical oncologists have been spearheading the use of CRS plus HIPEC for treating PM from gastric cancer. Hamazoe [55] and Yonemura [56] have reported the results of RCTs to verify the effect of HIPEC for the prophylaxis of peritoneal recurrence after curative resection of advanced gastric cancer. These two studies indicated that HIPEC is effective in preventing peritoneal recurrence of gastric cancer with serosal invasion.
In 2002, intraperitoneal chemotherapy using taxans was developed by Fushida for the treatment of PM from gastric cancer [25] , and led to the development of NIPS reported in 2006 [26] .
In 2009, extensive intra-operative peritoneal lavage (EIPL) was developed, and markedly improved the survival of patients with positive lavage cytology in prospective randomized clinical trials [57, 58] .
In 2016, the PSOGI group reviewed the latest results of CRS plus HIPEC for gastric cancer with PM [28] , and identified completeness of cytoreduction and PCI cut-off as independent prognostic factors.
